Skip to content
Sign in
SWC 2026 FinalistGrand Final: Lunch Block

Ocuwell Limited

University of Liverpool spin-off making corneal topography portable with OCUTOP, a handheld device matching reference machines.

Liverpool, United Kingdom, EuropeMedTech & devices, Portable ophthalmic diagnostics (corneal topography)
Stage
SeedNo documented AI
Product
PilotPilots / LOIs
Funding raised
$921Kdisclosed
Founded
20215 years ago
Founders
1Rania
Global score
4.0Grade DRank 89 of 151

Overview

University of Liverpool spin-off making corneal diagnosis accessible with a portable device for topography and dry eye assessment.

Traction

Pilots / LOIs

OCUTOP used by clinicians on first patients (testimonials from Royal Liverpool University Hospital, IAPB); commercialization still at the “register your interest” stage.

Market

Corneal topographers / ophthalmic diagnostics

Corneal topography and dry-eye assessment are needed for keratoconus, refractive surgery, contact lens fitting and clinical trials, but reference machines are bulky and expensive. A handheld device can extend diagnosis to optometrists, outreach and low-resource settings. Buyers are hospital ophthalmology departments, optometry practices and trial sponsors. Ocuwell is still at ‘register your interest’ stage after first clinical use.

Addressable market

2025
$0.8B
2030
$1.2B
+6.2% a year

Corneal topographers: $0.81bn in 2025 to $1.16bn in 2030 (CAGR 6.2%, Mordor Intelligence).

Customers

Ophthalmology departments, optometrists, eye-health NGOs, clinical trial sponsors

Who signs the cheque

Clinic owners and hospital procurement; sponsor clinical-operations teams

Geographies

  • United Kingdom

Drivers

  • Rising dry-eye and keratoconus diagnosis
  • Shift of eye care to community settings
  • Ophthalmic drug and cell-therapy trials needing corneal endpoints

Headwinds

  • Not yet on the market
  • Limited capital
  • Incumbent topographer vendors

Global corneal topographer market from $0.81bn in 2025 to $1.16bn in 2030 (CAGR 6.2%) according to Mordor Intelligence.

Scalability 5/10. Exportable portable device, but medical marking and a distribution network must be built region by region.

Market source: scotts-international.com

Technology

Category

Medical device (portable ophthalmic diagnostics)

No documented AI

Maturity

  1. R&D
  2. Prototype
  3. Pilot
  4. On the market
  5. Scaling

pilot

How it works

OCUTOP is a handheld device delivering corneal topography data equivalent to reference machines, with cloud solutions for data handling. No AI is mentioned.

Moat

Moderate: university IP and clinical validation; regulatory clearance would strengthen it.

Differentiation

Portable and lower-cost versus desktop topographers.

Integration points

  • Clinical trial data capture
  • Ophthalmology EHRs
  • Tele-ophthalmology platforms

Depends on

  • Regulatory clearance (UKCA/CE)
  • Manufacturing
  • Clinical validation

Use of AI

No use of AI mentioned

Product in detail

OCUTOP. handheld device providing corneal topography data equivalent to reference machines, with cloud solutions.

Business

Model
Device sales plus cloud services (planned).
Revenue logic
Not disclosed.
Go-to-market
Clinician adoption via Royal Liverpool University Hospital and IAPB networks.

Next milestones

  1. Regulatory clearance and first sales
  2. Clinical-trial endpoint use with a sponsor
  3. Seed extension

Key risks

  • Not on the market
  • Capital
  • Competition

Opportunities

3 found in the network

Concrete moves for Ocuwell Limited inside the network: who to sell to, sell through, build with or raise from, each with the reasoning, the evidence and the first step.

  • Customers 1
  • Co-development 1
  • Investors 1

Customers1

Who could buy, or sell through

Serve as portable dry-eye and corneal endpoint device in P002 trial

Pleryon's P002 dry-eye candidate is entering a first-in-human trial; sponsors need consistent corneal and dry-eye measurements across sites. OCUTOP's portable topography and dry-eye assessment could be a trial instrument, generating revenue and clinical credibility for Ocuwell.

25%confidence

Evidence from the records

  • “portable device for topography and dry eye assessment”
  • “First-in-human trial of candidate P002 (dry eye) authorized by Health Canada (ITA)”
If it works
Device leasing and data services for the trial sites.
First step
Email Pleryon's clinical team a one-page on OCUTOP as a trial endpoint tool.

Co-development1

An integration or joint product

Co-develop corneal monitoring for StemSight’s cell-therapy trials

StemSight's corneal cell therapy targets clinical trials around 2027 and will need repeated corneal surface measurements; Ocuwell's handheld topography could support follow-up, including outside specialist centres.

25%confidence

Evidence from the records

  • “handheld device providing corneal topography data equivalent to reference machines”
  • “Corneal cell therapy at preclinical stage, clinical trials targeted around 2027”
If it works
A pre-agreed device partner for StemSight's trial protocol.
First step
Arrange a call between both CEOs to align on trial timelines and endpoint needs.

Investors1

A fund whose thesis fits

Pitch Voima Ventures via StemSight

Voima invests at seed in European deep tech and life sciences and backed network member StemSight, a corneal therapy company; an ophthalmic diagnostic complements its portfolio.

15%confidence

Evidence from the records

  • “Voima Ventures, Business Finland, Stephen Industries, Biothom, Avohoidon Tutkimussäätiö”
  • “Deepbridge Capital, Northern Gritstone, LYVA Labs, University of Liverpool”
If it works
A European co-investor for the next round.
First step
Ask StemSight's founders for an intro to Voima Ventures.

Analyst reading of 21 Nov 2026, from the public record of the network. Method: analyst-ai.

Investors that fit

London seed firm of Robin and Saul Klein ($115M seed + $180M Latitude growth fund) behind Wise, Citymapper and Improbable.

UK portable ophthalmic diagnostics at seed — UK health deep tech.

40%confidence

Evidence from the records

  • “"Europe","United Kingdom"”
  • “Portable ophthalmic diagnostics (corneal topography)”
  • “OCUTOP used by clinicians on first patients (testimonials from Royal Liverpool University Hospital, IAPB)”
First step
Ask Northern Gritstone for an intro.

Finnish family office investing in life sciences; joined StemSight's €2.3M seed extension in 2025.

UK portable corneal topography diagnostics with first clinicians: cornea adjacency to StemSight, but UK-based and medtech.

20%confidence

Evidence from the records

  • “Portable ophthalmic diagnostics (corneal topography)”
  • “Seed”
Intro path
StemSight (Biothom portfolio, cornea peer)
First step
Explore a StemSight-OCUWELL clinical link before pitching Biothom.

Investment analysis

4.0D

Grade D

Rank 89 of 151

Disruption6.0/10
Business model3.0/10
Market3.0/10
Risk(lower is better)7.0/10

Global score = mean of disruption, model, market and (11 − risk). Last updated 21 Nov 2026.

Speculative, too early.

Disruption

6/10

Portable corneal topography: significant innovation in access to diagnosis.

Business model

3/10

Pilot clinical use, commercialization not launched.

Market

3/10

TAM corneal topographers / ophthalmic diagnostics ~$0.81bn (base 3), medium scalability 5/10 (0), no proven international expansion (0) → 3/10.

Risk

7/10

Lower is better

High risk: device regulation, USD 0.9M raised.

Strengths

  • University spin-off
  • Clinical testimonials

Risks

  • Not yet on the market
  • Limited capital

Funding

$921K, disclosed
  1. 1er août 2022 (Pipeseed)

    pre-seedUSD 306,423

    not specified

  2. déc. 2023

    pre-seedcumulative total ≈USD 921K

    not specified

  3. 31 oct. 2025 (CB Insights) / avril 2026 (Caplight)

    seednot disclosed

    Deepbridge Capital, Northern Gritstone, LYVA Labs, University of Liverpool

Amount used in the study. Cumulative pre-seed of ~$921K; 2025-2026 seed not quantified (up to $3.65M as upper bound).

Note. ≈USD 0.92M (VCBacked, through 2023); up to USD 3.65M according to other sources

Added a pre-seed round from August 2022 ($306K, Pipeseed, not verified by the press); site blocked (anti-bot check); no SWC qualification found.

Team

  • Rania Maklad

    Co-founder & CEO

    University of Liverpool spin-off specializing in corneal diagnostics.

Sources

Identification confidence
high
  1. 1ocuwell.com/
  2. 2news.liverpool.ac.uk/?p=121057
  3. 3caplight.com/company/ocuwell
  4. 4vcbacked.co/company/ocuwell
  5. 5pipeseed.com/investor/university-of-liverpool-559701

From the open study Startup World Cup 2026 by TIBOK, based on public sources, verified in November 2026. Scores are an analyst's judgment on an explicit grid, not the jury's.

Wall

Wall

No posts yet